NL-OMON34473已完成不适用
A double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability and pharmacokinetic properties of TV-1380 in healthy volunteers. - TV-1380 single rising dose study.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- TEVA Pharma
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy males, 18 - 45 years, BMI 18 and 30 kg/m2; weight is at least 50 kg; no smokers for at least 3 months.
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
A Double-Blind, Placebo-Controlled, Single Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX507-H in Healthy Male and Female SubjectsInflammatory bowel diseases10017969Crohn's diseaseNL-OMON36896Chemocentryx31
进行中（未招募）
1 期
A phase I, double-blind, placebo-controlled, ascending single intravenous dose, safety, tolerability, pharmacokinetic and pharmacodynamic study in healthy participants and non-cystic fibrosis bronchiectasis patients colonized with pseudomonas aeruginosa administered INFEX702ISRCTN17978477Infex Therapeutics44
已完成
1 期
Phase I study to assess the safety and tolerability of inhaled interferon-beta (IFN-beta1a) in controlled asthmatic male and female subjectsAsthmaISRCTN83107787Synairgen Research Limited (UK)40
已完成
不适用
Clinical trial to evaluate the safety and tolerability of CCX507-B in healthy subjectsISRCTN79241600ChemoCentryx, Inc. (USA)30
已完成
1 期
A single-dose, double-blind, placebo-controlled, randomised, crossover study of an oral cannabis-based medicine (ETC120) on sleep, cognition, and next-day function in adults with chronic insomnia disorderNeurological - Other neurological disordersInsomniaACTRN12619000714189Woolcock Institute of Medical Research20